GlassScriptPhysician profile
Anil N Patel
NPI 1205942281
$2,222.60
in general payments reported to CMS, 2019-2025
27 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $105 · 2021: $48.06 · 2022: $328 · 2023: $337 · 2024: $444 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $381.84 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $209.01 | 2019-2023 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $180.47 | 2022-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.37 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Paratek Pharmaceuticals, INC. | $125.24 | 2022-2025 | Nuzyra |
| United Therapeutics Corporation | $119.92 | 2021-2023 | |
| Insmed, INC. | $115.79 | 2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $86.67 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $84.71 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $74.28 | 2020-2023 | Prolastin-C Liquid |
| Genentech USA, INC. | $71.11 | 2019-2024 | Xolair |
| Sunovion Pharmaceuticals INC. | $67.22 | 2019-2020 | |
| Lilly USA, LLC | $62.07 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $61.35 | 2019-2024 | Breztri |
| Advanced Respiratory, INC | $58.15 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $55.27 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $47.51 | 2024 | Lumryz |
| Depuy Synthes Sales INC. | $47.38 | 2022 | |
| Genzyme Corporation | $40.41 | 2019 | |
| Gilead Sciences, INC. | $30.31 | 2019 | |
| Harmony Biosciences LLC | $23.42 | 2025 | |
| Axsome Therapeutics, INC. | $22.23 | 2025 | Sunosi |
| Pulmonx Corporation | $20.50 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Pfizer INC. | $18.59 | 2024 | |
| Baxter Healthcare | $18.59 | 2022 | |
| Circassia INC. | $14.58 | 2019 | |
| Electromed, INC. | $13.61 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.